Alliance for Pandemic Preparedness

May 21, 2021

Infection and Vaccine-Induced Neutralizing Antibody Responses to the SARS-CoV-2 B.1.617.1 Variant

Category:

Topic:

Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] An in-vitro study of neutralizing antibody response to the B.617.1 variant found that the variant was 6.8-fold more resistant to neutralization by sera from persons previously infected with SARS-CoV-2 (N=24) and individuals vaccinated with either the Pfizer-BioNTech (N=10) or Moderna (N=15) vaccines compared to a wild type strain. However, 79% of serum samples from persons previously infected with SARS-CoV-2 and all those from vaccinated persons were still able to neutralize the virus, suggesting that mRNA vaccines will remain effective against this variant. 

Edara et al. (May 10, 2021). Infection and Vaccine-Induced Neutralizing Antibody Responses to the SARS-CoV-2 B.1.617.1 Variant. Pre-print downloaded May 21 from: The Preprint Server for Biology. https://doi.org/10.1101/2021.05.09.443299